Jersey City, NJ, United States
Jersey City, NJ, United States

Time filter

Source Type

BASKING RIDGE, N.J., Nov. 7, 2016 /PRNewswire/ -- Reproductive Medicine Associates of New Jersey (RMANJ), a world-renowned leader in the field of infertility, today announced that their Helping Heroes Build Families program would continue into 2017 – its fifth year. Through the program,...


Kim T.J.,Reproductive Medicine Associates of New Jersey | Kim T.J.,Fertility Center | Hong S.W.,Fertility Center
Journal of Assisted Reproduction and Genetics | Year: 2011

Objective: To report a birth of a healthy boy after long-term cryopreservation of oocytes by vitrification. Design: Clinical application. Setting: IVF Center. Patient: A 17 year-old female with secondary pulmonary hypertension caused by transposition of great vessels visited our center in 2002, and she wished oocytes cryopreservation to avoid possible sterility after the following category X medication treatment. Intervention(s): Vitrified oocytes on Electron Microscope (EM) grids were warmed after 5 years of storage. Surviving MII oocytes were microinjected for fertilization and two embryos were transferred into a gestational carrier day 5 after microinjection. Main Outcome Measure(s): Survival, fertilization, cleavage, clinical pregnancy and delivery. Result(s): Eleven out of fourteen oocytes (78.6%) survived warming. Eight Metaphase II (MII) oocytes and 3 in vitro matured oocytes were microinjected; all 11 oocytes (100%) fertilized and 2 embryos were transferred on day 5. A healthy baby boy weighing 3,600 g was delivered at 38 weeks of gestation. Live-birth rates per warmed oocyte and per injected oocyte were 7.1% and 9.1% respectively. Conclusion(s): Cryopreservation after vitrification with EM grids maintained the developmental competence of oocytes after long-term storage and resulted in a successful live birth. © 2010 Springer Science+Business Media, LLC.


Franasiak J.M.,Rutgers University | Forman E.J.,Rutgers University | Hong K.H.,Rutgers University | Werner M.D.,Rutgers University | And 3 more authors.
Fertility and Sterility | Year: 2014

Objective To determine the relationship between the age of the female partner and the prevalence and nature of human embryonic aneuploidy. Design Retrospective. Setting Academic. Patient(s) Trophectoderm biopsies. Intervention(s) Comprehensive chromosomal screening performed on patients with blastocysts available for biopsy. Main Outcome Measure(s) Evaluation of the impact of maternal age on the prevalence of aneuploidy, the probability of having no euploid embryos within a cohort, the complexity of aneuploidy as gauged by the number of aneuploid chromosomes, and the trisomy/monosomy ratio. Result(s) Aneuploidy increased predictably after 26 years of age. A slightly increased prevalence was noted at younger ages, with >40% aneuploidy in women 23 years and under. The no euploid embryo rate was lowest (2% to 6%) in women aged 26 to 37, was 33% at age 42, and was 53% at age 44. Among the biopsies with aneuploidy, 64% involved a single chromosome, 20% two chromosomes, and 16% three chromosomes, with the proportion of more complex aneuploidy increasing with age. Finally, the trisomy/monosomy ratio approximated 1 and increased minimally with age. Conclusion(s) The lowest risk for embryonic aneuploidy was between ages 26 and 30. Both younger and older age groups had higher rates of aneuploidy and an increased risk for more complex aneuploidies. The overall risk did not measurably change after age 43. Trisomies and monosomies are equally prevalent. © 2014 American Society for Reproductive Medicine, Published by Elsevier Inc.


Scott Jr. R.T.,Reproductive Medicine Associates of New Jersey | Scott Jr. R.T.,Rutgers University | Upham K.M.,Reproductive Medicine Associates of New Jersey | Forman E.J.,Rutgers University | And 3 more authors.
Fertility and Sterility | Year: 2013

Objective: To determine if cleavage- or blastocyst-stage embryo biopsy affects reproductive competence. Design: Paired randomized clinical trial. Setting: Academic-assisted reproduction program. Patient(s): Attempting conception through IVF. Intervention(s): After selecting two embryos for transfer, one was randomized to biopsy and the other to control. Both were transferred within shortly thereafter. The biopsy was submitted for microarray analysis and single-nucleotide polymorphism (SNP) profiling. Buccal DNA obtained from the neonate after delivery had microarray analysis and SNP profile compared with that of the embryonic DNA. A match confirmed that the biopsied embryo implanted and developed to term, whereas a nonmatch indicated that the control embryo had led to the delivery. Main Outcome Measure(s): Paired analysis of the delivery rates of the transferred embryos. Either twin delivery or failure to deliver represents equivalent outcomes for the biopsied and control embryos. In contrast, singletons were determined to be from the biopsied or the control embryo. Result(s): Blastomere biopsy on day 3 of development resulted in a significant reduction in sustained implantation. Only 30% of biopsied embryos had sustained implantation and ultimately developed into live-born infants versus 50% of unbiopsied controls, a relative reduction of 39%. In contrast, sustained implantation rates were equivalent (51% vs. 54%) for biopsied and control blastocysts. Conclusion(s): Cleavage-stage biopsy markedly reduced embryonic reproductive potential. In contrast, trophectoderm biopsy had no measurable impact and may be used safely when embryo biopsy is indicated. Clinical Trial Registration Number: NCT01219504. © 2013 by American Society for Reproductive Medicine.


Treff N.R.,Reproductive Medicine Associates of New Jersey | Treff N.R.,University of New Brunswick | Treff N.R.,Rutgers University | Scott Jr. R.T.,Reproductive Medicine Associates of New Jersey | Scott Jr. R.T.,University of New Brunswick
Fertility and Sterility | Year: 2013

Embryonic comprehensive chromosomal euploidy may represent a powerful biomarker to improve the success of IVF. However, there are a number of aneuploidy screening strategies to consider, including different technologic platforms with which to interrogate the embryonic DNA, and different embryonic developmental stages from which DNA can be analyzed. Although there are advantages and disadvantages associated with each strategy, a series of experiments producing evidence of accuracy, safety, clinical predictive value, and clinical efficacy indicate that trophectoderm biopsy and quantitative real-time polymerase chain reaction (qPCR)-based comprehensive chromosome screening (CCS) may represent a useful strategy to improve the success of IVF. This Biomarkers in Reproductive Medicine special issue review summarizes the accumulated experience with the development and clinical application of a 4-hour blastocyst qPCR-based CCS technology. Copyright © 2013 American Society for Reproductive Medicine, Published by Elsevier Inc.


Treff N.R.,Reproductive Medicine Associates of New Jersey | Treff N.R.,University of New Brunswick | Treff N.R.,Rutgers University
Seminars in Reproductive Medicine | Year: 2012

An exciting era in preimplantation genetic diagnosis (PGD) is emerging with the adaptation and development of new high throughput genome-wide methodologies for the evaluation of aneuploidy. In fact, many promising preclinical studies and clinical trials involving comprehensive chromosome screening (CCS) have renewed clinician interest in the use of PGD for aneuploidy screening as an embryo selection tool to improve the success of in vitro fertilization (IVF). This review will provide an overview of the basic underlying features and applications of the growing number of platforms and strategies for preimplantation genome-wide analysis of aneuploidy. Copyright © 2012 by Thieme Medical Publishers, Inc.


Treff N.R.,Reproductive Medicine Associates of New Jersey | Treff N.R.,University of New Brunswick | Su J.,Reproductive Medicine Associates of New Jersey | Taylor D.,Reproductive Medicine Associates of New Jersey | And 3 more authors.
PLoS Genetics | Year: 2011

Aneuploidy represents the most prevalent form of genetic instability found in human embryos and is the leading genetic cause of miscarriage and developmental delay in newborns. Telomere DNA deficiency is associated with genomic instability in somatic cells and may play a role in development of aneuploidy commonly found in female germ cells and human embryos. To test this hypothesis, we developed a method capable of quantifying telomere DNA in parallel with 24-chromosome aneuploidy screening from the same oocyte or embryo biopsy. Aneuploid human polar bodies possessed significantly less telomere DNA than euploid polar bodies from sibling oocytes (-3.07 fold, P = 0.016). This indicates that oocytes with telomere DNA deficiency are prone to aneuploidy development during meiosis. Aneuploid embryonic cells also possessed significantly less telomere DNA than euploid embryonic cells at the cleavage stage (-2.60 fold, P = 0.002) but not at the blastocyst stage (-1.18 fold, P = 0.340). The lack of a significant difference at the blastocyst stage was found to be due to telomere DNA normalization between the cleavage and blastocyst stage of embryogenesis and not due to developmental arrest of embryos with short telomeres. Heterogeneity in telomere length within oocytes may provide an opportunity to improve the treatment of infertility through telomere-based selection of oocytes and embryos with reproductive competence. © 2011 Treff et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


VALENCIA, Spain and BASKING RIDGE, N.J., Feb. 16, 2017 /PRNewswire/ -- The management division of Reproductive Medicine Associates of New Jersey (RMANJ) and The Valencian Infertility Institute (IVI) announced they are combining their businesses to create a new company called IVI-RMA...


Forman E.J.,Reproductive Medicine Associates of New Jersey | Hong K.H.,Reproductive Medicine Associates of New Jersey | Franasiak J.M.,Reproductive Medicine Associates of New Jersey | Scott Jr. R.T.,Reproductive Medicine Associates of New Jersey
American Journal of Obstetrics and Gynecology | Year: 2014

Objective We sought to determine whether performing elective single embryo transfer (eSET) after trophectoderm biopsy and rapid aneuploidy screening results in improved obstetrical and neonatal outcomes compared with transferring 2 untested embryos. Study Design The Blastocyst Euploid Selective Transfer (BEST) Trial enrolled infertile couples with a female partner up to age 42 years who were undergoing in vitro fertilization. They were randomized to receive transfer of a single euploid embryo (eSET) or to the standard of care with transfer of 2 embryos that were not biopsied for aneuploidy screening (untested 2-embryo transfer). Gestational age at delivery, birthweight, and neonatal intensive care unit (NICU) lengths of stay were compared with Mann-Whitney U. The risk of preterm delivery, low birthweight, and NICU admission were compared with χ2. Results Among the 175 randomized patients, the delivery rates were similar (69% after euploid eSET vs 72% after untested 2-embryo transfer; P =.6) through the fresh cycle and up to 1 frozen transfer, with a dramatic difference in multiple births (1.6% vs 47%; P <.0001). The risk of preterm delivery (P =.03), low birthweight (P =.002), and NICU admission (P =.04) were significantly higher after untested 2-embryo transfer. Babies born after untested 2-embryo transfer spent >5 times as many days in the NICU (479 vs 93 days; P =.03). Conclusion By enhancing embryo selection with a validated method of aneuploidy screening, a single euploid embryo with high reproductive potential can be selected for transfer. Using this approach, eSET can be performed without compromising delivery rates and improving the chance of having a healthy, term singleton delivery after in vitro fertilization. © 2014 Mosby, Inc. All rights reserved.


Gardner D.K.,University of Melbourne | Meseguer M.,Laboratorio Fiv | Rubio C.,Igenomix And Fundacion Instituto Valenciano Of Infertilidad Fivi Incliva | Treff N.R.,Reproductive Medicine Associates of New Jersey
Human Reproduction Update | Year: 2015

BACKGROUND: Transfer of more than a single embryo in an IVF cycle comes with the finite possibility of a multiple gestation. Even a twin pregnancy confers significant risk to both mother and babies. The move to single-embryo transfer for all patients will be greatly facilitated by the ability to quantify embryo viability. Developments in time-lapse incubation systems have provided new insights into the developmental kinetics of the human preimplantation embryo. Advances in molecular methods of chromosomal analysis have created platforms for highly effective screening of biopsied embryos, while noninvasive analysis of embryo physiology reveals more about the embryo than can be determined by morphology alone. METHODS: Recent developments in time-lapse microscopy, molecular karyotyping and in proteomics and metabolomics have been assessed and presented here in a descriptive review. RESULTS AND CONCLUSIONS: New algorithms are being created for embryo selection based on their developmental kinetics in culture, and the impact of factors such as patient etiology and treatment are being clarified. Potential links between morphokinetic data and embryo karyotype are being elucidated. The introduction of new molecular methods of determining embryo chromosomal complement is proving to be accurate and reproducible, with the future trending toward CGH arrays or next generation sequencing as a rapid and reliable means of analysis, that should be suitable for each IVF clinic to adopt. A relationship between embryo metabolism and viability is established and is now being considered together with morphokinetic data to create more robust algorithms for embryo selection. Microfluidic devices have the capacity and potential to be used in human IVF clinics for the routine diagnosis of embryo biomarkers. © The Author 2015. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.

Loading Reproductive Medicine Associates of New Jersey collaborators
Loading Reproductive Medicine Associates of New Jersey collaborators